Laboratory Introduction
Chimeric antigen receptor cell immunotherapy (CAR-T) is a new type of immunotherapy that engineers’ human immune cells to kill tumors. It has achieved remarkable results in leukemia, lymphoma, and multiple myeloma, and there are currently many commercial products worldwide. However, significant challenges remain in enhancing its efficacy against solid tumors. The Zhou Laboratory at CIMR is dedicated to developing and optimizing next-generation CAR-T cell therapies, with a particular focus on innovative cell engineering strategies to improve their effectiveness in solid tumors.
Lab website：https://www.cimrbj.ac.cn/en/channel/1897910866058285056.html
A. Major Research Projects
The laboratory will comprehensively utilize molecular biology, cell biology, flow cytometry, mouse tumor models, high-throughput sequencing, and other technologies and methods to research the following topics (not limited):
a. Explore the potential of CAR-NKT cell therapy in pancreatic cancer and other solid tumors.
b. Develop and refine new strategies to enhance CAR-T cell persistence, improving the effectiveness of CAR-T therapy in solid tumors.
c. High-throughput sequencing screening to understand the mechanism of tumor cell tolerance to CAR-T therapy, to guide targeted combined treatment methods.
B. Major Contributions
a. Generating the murine CAR NKT platform and demonstrating their superior anti-tumor effect in multiple solid tumors via programming the tumor microenvironment (Nature Cancer, 2024).
b. Enhancing the efficacy of CAR-T treatment by modifying CAR structure (Journal for Immunotherapy of Cancer, 2021; Nature Cancer, 2021; Cellular & Molecular Immunology, 2024) (Patent, 2021, WO2023199069A1).
c. Identifying the new mechanism to regulate inflammation and macrophage polarization (Cell Reports, 2019, 2020; The Journal of Clinical Investigation, 2015).
C. Representative Publications
Nature Cancer, 2024 Nov; 5(11): 1607-1621. PMID: 39354225.
Cellular & Molecular Immunology, 2024 Aug; 21(8): 905-917. PMID: 38937625.
Journal for Immunotherapy of Cancer, 2021 Apr; 9(4): e002173. PMID: 33795386.
Cell Reports. 2019 Apr 23; 27(4): 1176-1189.e5. PMID: 31018132.
Open Positions
Main Responsibilities
a. Conducting research projects independently.
b. Assisting PI to mentor graduate students, and write grant proposals and manuscripts.
Qualifications
a. Backgrounds in biology or biomedical fields. Either about obtaining a Ph.D. or recently obtaining a Ph.D. degree (ideally within the last 3 years).
b. Published or about to publish research papers as the first author in reputable journals in the field.
c. Have the ability to independently carry out scientific research and guide graduate students and have scientific research enthusiasm and rigorous scientific research attitude.
d. Strong research experience in molecular biology, immune cell culture, FACS, and mice experiments.
e. Proficient in English reading, writing, and daily communication. Capable of writing papers in English.
Welfare Treatment
a. Competitive salary based on the applicant’s work experience and ability (salary negotiable).
b. Social insurance and housing fund, supplementary medical insurance, physical examination and paid annual leave.
c. Opportunities for career development and available professional guidance.
How to apply
To apply, please send a personal resume, research interest or plan, the names and contacts of 2-3 referees, and other materials demonstrating research capabilities to zhouxin@cimrbj.ac.cn and indicate the applicant's name and specific job position in the email subject.
Contact Person: Xin Zhou
Contact address: No.10 Xitoutiao, Youanmenwai, Fengtai District, Beijing
This recruitment is valid for the long term until a suitable candidate is recruited.
Additionally, our laboratory welcomes interns and joint trainees at all stages who are interested in cellular immunotherapy to come and exchange ideas.
10 Xitoutiao, Youanmen Wai, Fengtai District, Beijing 100069, China
010-86738999
cimr@cimrbj.ac.cn
中文
